Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Heart Failure × Hydroxymethylglutaryl-CoA Reductase Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 2 Ovarian Neoplasms 1 Neoplasms 1 Heart Failure 1 Endometrial Neoplasms 1 Endometrial Hyperplasia 1 Cardiotoxicity 1 Breast Neoplasms 1

Interventions

Control Groups 2 Atorvastatin 2 pertuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 candesartan 1 Trastuzumab 1 Sodium Chloride 1 Simendan 1 Pyruvic Acid 1 Population Groups 1 Ogivri 1 Metoprolol 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Eplerenone 1 Carvedilol 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03186404 2022-02-08

SPARE-HF

University Health Network, Toronto

Phase 2 Unknown

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡